Technical Analysis for RARX - Ra Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 23.66 1.37% 0.32
RARX closed up 1.37 percent on Friday, May 24, 2019, on 50 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical RARX trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
NR7 Range Contraction 0.00%
20 DMA Support Bullish 1.37%
50 DMA Support Bullish 1.37%
Hammer Candlestick Bullish 1.37%
NR7 Range Contraction 1.11%
NR7-2 Range Contraction 1.11%
Crossed Above 20 DMA Bullish 1.55%
Crossed Above 50 DMA Bullish 1.55%

Older signals for RARX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Its peptide chemistry platform delivers enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. The company's lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It also develops Factor D inhibition for age-related macular degeneration and geographic atrophy; Oral C5 inhibitor for refractory generalized myasthenia gravis, lupus nephritis, and central nervous system (CNS) diseases; C1s inhibition for autoimmune/CNS diseases. The company has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Medicine Biopharmaceutical Medical Specialties Diseases Immunology Antibodies Autoimmune Diseases Rare Diseases Age Related Macular Degeneration Autoimmunity Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Myasthenia Gravis Lupus Nephritis Pnh Therapeutics For The Treatment Of Diseases
Is RARX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 27.68
52 Week Low 6.12
Average Volume 424,913
200-Day Moving Average 18.255
50-Day Moving Average 23.0786
20-Day Moving Average 23.0695
10-Day Moving Average 23.535
Average True Range 1.3965
ADX 12.16
+DI 18.1538
-DI 16.364
Chandelier Exit (Long, 3 ATRs ) 20.7605
Chandelier Exit (Short, 3 ATRs ) 25.3695
Upper Bollinger Band 24.7834
Lower Bollinger Band 21.3556
Percent B (%b) 0.67
BandWidth 14.85858
MACD Line 0.2782
MACD Signal Line 0.2604
MACD Histogram 0.0178
Fundamentals Value
Market Cap 534.92 Million
Num Shares 22.6 Million
EPS -2.84
Price-to-Earnings (P/E) Ratio -8.33
Price-to-Sales 0.00
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.07
Resistance 3 (R3) 25.01 24.49 24.84
Resistance 2 (R2) 24.49 24.13 24.52 24.76
Resistance 1 (R1) 24.07 23.91 24.28 24.13 24.68
Pivot Point 23.55 23.55 23.65 23.58 23.55
Support 1 (S1) 23.13 23.19 23.34 23.19 22.64
Support 2 (S2) 22.61 22.97 22.64 22.56
Support 3 (S3) 22.19 22.61 22.49
Support 4 (S4) 22.25